Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)

Pancreatic Cancer Clinical Trial

Official title:

An Open-Labeled, Randomized Phase II Trial of Adjuvant Chemotherapy in Combination With Stereotactic Body Radiation Therapy (SBRT) Versus Adjuvant Chemotherapy Alone for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02461836
• Other study ID #: YAN2015-030
• Status: Recruiting
• Phase: Phase 2
• First received: May 28, 2015
• Last updated: April 4, 2017
• Start date: August 2015
• Est. completion date: June 2020

Study information

• Verified date: April 2017
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Tingbo Liang, MD PHD
• Phone: 0571-87315006
• Email: liangtingbo[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pancreatic cancer is one of the deadliest tumor types of the alimentary system. Resection is the only curable method to treat pancreatic cancer. However, even if radical resection is achieved, the 5-year survival rate is still low because of tumor recurrence. It's reported adjuvant radiation can prolong survival and improve quality of life after surgery. For R0 (microscopic negative margin) resection patients with advanced stages (T3 or N1), the value of adjuvant radiation is still in debate. It's warranted to explore the role of adjuvant radiation for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1) in large, prospective, and randomized cohorts.

The application of Stereotactic Body Radiation Therapy (SBRT) makes radiation less harmful and more flexible. It is hoped that adjuvant SBRT may benefit post-operative patients with advanced stages and one day adjuvant SBRT combined with chemotherapy become the standard of care for pancreatic cancer patients.

Description:

Pancreatic cancer is one of the deadliest tumor types of the alimentary system. Despite of the dramatic progress of diagnostic methods and surgical technics, the overall 5-year survival is still around 5%. Resection is the only curable method to treat pancreatic cancer, although only a small proportion of patients are eligible for operation. However, even if radical resection is achieved, the 5-year survival rate is only 15-20%. The main cause of death is tumor recurrence, which is as high as 50-70% in 3 years after operation. By now, it is widely accepted that pancreatic cancer is a systemic disease. Systemic treatments are recommended in neoadjuvant and adjuvant manners. It's reported adjuvant radiation can prolong survival and improve quality of life after surgery, especially for patients who undergo a R1 (microscopic positive margin) and R2 (macroscopic positive margin) resection. For R0 (microscopic negative margin) resection patients with advanced stages (T3 or N1), the value of adjuvant radiation is still in debate. Some argues adjuvant radiation after radical resection makes no effect on preventing local recurrence and metastasis but may impair patients' quality of life and overall survival. On the contrary, some other researchers draw the conclusion that adjuvant radiation may facilitate the local control of tumor recurrence in small cohorts. It's warranted to explore the role of adjuvant radiation for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1) in large, prospective, and randomized cohorts.

Traditionally, radiation may take more than one month to deliver and the dosage is restricted to prevent damage to surrounding tissues. The size effects and duration impair patients' compliance. Recently, the application of Stereotactic Body Radiation Therapy (SBRT) makes radiation less harmful and more flexible. The advantages of SBRT are higher dosage of radiation, less damage to surrounding organs, and significant reduce of duration. To our knowledge, there is no big randomized clinical trial to evaluate the value of SBRT for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1). It is hoped that adjuvant SBRT may benefit post-operative patients with advanced stages and one day adjuvant SBRT combined with chemotherapy become the standard of care for pancreatic cancer patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 513
• Est. completion date: June 2020
• Est. primary completion date: June 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male/Female subjects, age = 18 years and = 75 years old at the time informed consent is signed

2. Pathologically confirmed pancreatic adenocarcinoma or mixed-type pancreatic carcinoma (adenocarcinoma predominantly)

3. The operation must be radical resection (R0), with all margins negative.

4. Eastern Cooperative Oncology Group (ECOG) score: 0-2

5. Without large volume ascites or pleural effusion

6. Lab tests:

a Complete blood cell count: HGB=100g/L, WBC=4×109/L, PLT=100×109/L b Liver function:

Total bilirubin=3 x upper limit of normal range (ULN) with direct bilirubin within normal range, alanine aminotransferase (ALT) / aspartate aminotransferase (AST)=3 c Renal function: Creatine=1.5 x ULN or creatine clearance=60 ml/min

7. Heart and lung function well (Eject function>55%)

8. Females of child-bearing potential must demonstrate a negative serum pregnancy test result at screening confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of Gemcitabine.

9. At least 30 days from major surgery before randomization, with full recovery

10. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted

11. Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

1. Margin positive resections (R1 or R2)

2. Resection of recurrence pancreatic cancer

3. Other types of pancreatic cancer (non-adenocarcinoma)

4. Subjects with severe complications, can't tolerate chemotherapy in 4-12 weeks after surgery

5. Subjects with severe bone marrow suppression

6. Subjects with a history of severe lung diseases (interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis), severe liver diseases (active hepatitis, liver cirrhosis), renal dysfunction, uncontrolled diabetes and hypertension, or multiple and severe allergies which may lead to serious complications

7. Subjects with severe heart diseases (congested heart failure, systematic coronary disease, uncontrolled arrhythmia, or myocardial infarction in 6 months)

8. Under treatment with steroids for a long time

9. Subjects with early recurrence of pancreatic cancer before initiation of chemotherapy

10. Subjects with diarrhea and infection (body temperature >38.5?)

11. Subjects who was enrolled into another clinical study or finished another clinical study within the previous 4 weeks prior to randomization

12. Pregnant or nursing women

13. Subjects with other type of malignancies, except of curated basal cell carcinoma and carcinoma in situ of cervix which finished treatments more than half one year ago

14. Subjects having any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent them from participating in the study

15. Any condition that confounds interpreting data from the study

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Gemcitabine
Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)

Radiation:
• SBRT
Protocol: 5 Gy/d, for 5 consecutive days

Locations

Country	Name	City	State
China	the second affiliated hospital of Zhejiang University	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease-free survival (DFS)		Up to approximately 36 months
Secondary	overall survival (OS)		Up to approximately 60 months
Secondary	quality of life (QOL) as assessed by the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-PAN26 score		Up to approximately 60 months
Secondary	safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4	according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4	Up to approximately 8 months